This mutation should be validated in a clinical setting as it may be important in the use of Aurora B inhibitors and resistance to therapy, much as the T315I BCR-ABL mutation is highly prognostic of outcome for Imatinib treatment in CML patients. Here, AURKB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.